GLP-1 Receptor Agonist
Also known as: GLP-1, incretin therapy, semaglutide, liraglutide, tirzepatide
A class of medications that activate the GLP-1 receptor, used for type 2 diabetes and obesity. Major trials (LEADER, SUSTAIN-6, SELECT) established cardiovascular and weight outcomes for specific agents and populations.